{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:11:20Z","timestamp":1793257880877,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40262-025-01597-y","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T03:04:17Z","timestamp":1767495857000},"page":"405-415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Population Pharmacokinetics of Intravenous Cefuroxime in Plasma and Bone of Patients with Prosthetic Joint Infection: Is There Room for Dose Optimization?"],"prefix":"10.1007","volume":"65","author":[{"given":"Gerbert Coen","family":"de Waard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaolin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewout S.","family":"Veltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"van Oldenrijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Koen","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Bahmany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Preijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1202-3643","authenticated-orcid":false,"given":"Birgit C. P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"key":"1597_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12185908","author":"HK Yoon","year":"2023","unstructured":"Yoon HK, Yoo JH, Oh HC, Ha JW, Park SH. The incidence rate, microbiological etiology, and results of treatments of prosthetic joint infection following total knee arthroplasty. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12185908.","journal-title":"J Clin Med"},{"issue":"1","key":"1597_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-023-04060-5","volume":"18","author":"ZJ Zeng","year":"2023","unstructured":"Zeng ZJ, Yao FM, He W, Wei QS, He MC. Incidence of periprosthetic joint infection after primary total hip arthroplasty is underestimated: a synthesis of meta-analysis and bibliometric analysis. J Orthop Surg Res. 2023;18(1):610. https:\/\/doi.org\/10.1186\/s13018-023-04060-5.","journal-title":"J Orthop Surg Res"},{"issue":"8","key":"1597_CR3","doi-asserted-by":"publisher","first-page":"732.e1\u20138","DOI":"10.1016\/j.cmi.2016.05.004","volume":"22","author":"N Benito","year":"2016","unstructured":"Benito N, Franco M, Ribera A, Soriano A, Rodriguez-Pardo D, Sorl\u00ed L, et al. Time trends in the aetiology of prosthetic joint infections: a multicentre cohort study. Clin Microbiol Infect. 2016;22(8):732.e1-8. https:\/\/doi.org\/10.1016\/j.cmi.2016.05.004.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"1597_CR4","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/j.1469-0691.2012.04011.x","volume":"18","author":"W Zimmerli","year":"2012","unstructured":"Zimmerli W. Orthopaedic device-associated infection. Clin Microbiol Infect. 2012;18(12):1160\u20131. https:\/\/doi.org\/10.1111\/j.1469-0691.2012.04011.x.","journal-title":"Clin Microbiol Infect"},{"key":"1597_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4137\/CMAMD.S10859","volume":"5","author":"M Bhandari","year":"2012","unstructured":"Bhandari M, Smith J, Miller LE, Block JE. Clinical and economic burden of revision knee arthroplasty. Clin Med Insights Arthritis Musculoskelet Disord. 2012;5:89\u201394.","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"issue":"1","key":"1597_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2106\/00004623-199401000-00006","volume":"76","author":"DR Mauerhan","year":"1994","unstructured":"Mauerhan DR, Nelson CL, Smith DL, Fitzgerald RH Jr., Slama TG, Petty RW, et al. Prophylaxis against infection in total joint arthroplasty. One day of cefuroxime compared with three days of cefazolin. J Bone Jt Surg Am. 1994;76(1):39\u201345. https:\/\/doi.org\/10.2106\/00004623-199401000-00006.","journal-title":"J Bone Jt Surg Am"},{"issue":"3","key":"1597_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMra2203477","volume":"388","author":"R Patel","year":"2023","unstructured":"Patel R. Periprosthetic joint infection. N Engl J Med. 2023;388(3):251\u201362. https:\/\/doi.org\/10.1056\/NEJMra2203477.","journal-title":"N Engl J Med"},{"key":"1597_CR8","first-page":"467","volume":"65","author":"J Bosco","year":"2016","unstructured":"Bosco J, Bookman J, Slover J, Edusei E, Levine B. Principles of antibiotic prophylaxis in total joint arthroplasty: current concepts. Instr Course Lect. 2016;65:467\u201375.","journal-title":"Instr Course Lect"},{"issue":"11","key":"1597_CR9","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1111\/jphp.12282","volume":"66","author":"U Gergs","year":"2014","unstructured":"Gergs U, Clauss T, Ihlefeld D, Weiss M, P\u00f6nicke K, Hofmann GO, et al. Pharmacokinetics of ceftriaxone in plasma and bone of patients undergoing hip or knee surgery. J Pharm Pharmacol. 2014;66(11):1552\u20138. https:\/\/doi.org\/10.1111\/jphp.12282.","journal-title":"J Pharm Pharmacol"},{"issue":"7","key":"1597_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/cpdd.418","volume":"7","author":"U Gergs","year":"2018","unstructured":"Gergs U, Ihlefeld D, Clauss T, Weiss M, P\u00f6nicke K, Hofmann GO, et al. Population pharmacokinetics of levofloxacin in plasma and bone of patients undergoing hip or knee surgery. Clin Pharmacol Drug Dev. 2018;7(7):692\u20138.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1597_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12121738","author":"SA Zelenitsky","year":"2023","unstructured":"Zelenitsky SA. Effective antimicrobial prophylaxis in surgery: the relevance and role of pharmacokinetics-pharmacodynamics. Antibiotics. 2023. https:\/\/doi.org\/10.3390\/antibiotics12121738.","journal-title":"Antibiotics"},{"issue":"6","key":"1597_CR12","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1053\/j.jvca.2015.03.026","volume":"29","author":"J Trent Magruder","year":"2015","unstructured":"Trent Magruder J, Grimm JC, Dungan SP, Shah AS, Crow JR, Shoulders BR, et al. Continuous intraoperative cefazolin infusion may reduce surgical site infections during cardiac surgical procedures: a propensity-matched analysis. J Cardiothorac Vasc Anesth. 2015;29(6):1582\u20137. https:\/\/doi.org\/10.1053\/j.jvca.2015.03.026.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"9","key":"1597_CR13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/17425255.2022.2117607","volume":"18","author":"BCP Koch","year":"2022","unstructured":"Koch BCP, Zhao Q, Oosterhoff M, van Oldenrijk J, Abdulla A, de Winter BCM, et al. The mysteries of target site concentrations of antibiotics in bone and joint infections: what is known? A narrative review. Expert Opin Drug Metab Toxicol. 2022;18(9):587\u2013600.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"219","key":"1597_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.114904","volume":"20","author":"S Bahmany","year":"2022","unstructured":"Bahmany S, Abdulla A, Ewoldt TMJ, Oehlers PL, de Winter BCM, Koch BCP. High-throughput analysis for the simultaneous quantification of nine beta-lactam antibiotics in human plasma by UPC(2)-MS\/MS: method development, validation, and clinical application. J Pharm Biomed Anal. 2022;20(219):114904.","journal-title":"J Pharm Biomed Anal"},{"key":"1597_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2024.124169","volume":"1241","author":"S Bahmany","year":"2024","unstructured":"Bahmany S, Holst A, Hoogendoorn MH, Oosterhoff M, van Oldenrijk J, Bos PK, et al. Quantification of cefuroxime and flucloxacillin in synovial tissue and bone using ultra-performance convergence chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2024;1241:124169. https:\/\/doi.org\/10.1016\/j.jchromb.2024.124169.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"4","key":"1597_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1179\/joc.2002.14.4.361","volume":"14","author":"E Boselli","year":"2002","unstructured":"Boselli E, Breilh D, Bel JC, Debon R, Saux MC, Chassard D, et al. Diffusion of isepamicin into cancellous and cortical bone tissue. J Chemother. 2002;14(4):361\u20135. https:\/\/doi.org\/10.1179\/joc.2002.14.4.361.","journal-title":"J Chemother"},{"issue":"2","key":"1597_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1179\/joc.2003.15.2.134","volume":"15","author":"D Breilh","year":"2003","unstructured":"Breilh D, Boselli E, Bel JC, Chassard D, Saux MC, Allaouchiche B. Diffusion of cefepime into cancellous and cortical bone tissue. J Chemother. 2003;15(2):134\u20138. https:\/\/doi.org\/10.1179\/joc.2003.15.2.134.","journal-title":"J Chemother"},{"issue":"3","key":"1597_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2146\/ajhp120568","volume":"70","author":"DW Bratzler","year":"2013","unstructured":"Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health-Syst Pharm. 2013;70(3):195\u2013283. https:\/\/doi.org\/10.2146\/ajhp120568.","journal-title":"Am J Health-Syst Pharm"},{"key":"1597_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02241-17","author":"SA Alqahtani","year":"2018","unstructured":"Alqahtani SA, Alsultan AS, Alqattan HM, Eldemerdash A, Albacker TB. Population pharmacokinetic model-based evaluation of standard dosing regimens for cefuroxime used in coronary artery bypass graft surgery with cardiopulmonary bypass. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/aac.02241-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"1597_CR20","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1093\/jac\/dku195","volume":"69","author":"M Carlier","year":"2014","unstructured":"Carlier M, No\u00eb M, Roberts JA, Stove V, Verstraete AG, Lipman J, et al. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures. J Antimicrob Chemother. 2014;69(10):2797\u2013803. https:\/\/doi.org\/10.1093\/jac\/dku195.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"1597_CR21","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/apm.12996","volume":"127","author":"M T\u00f8ttrup","year":"2019","unstructured":"T\u00f8ttrup M, S\u00f8balle K, Bibby BM, Hardlei TF, Hansen P, Fuursted K, et al. Bone, subcutaneous tissue and plasma pharmacokinetics of cefuroxime in total knee replacement patients\u2014a randomized controlled trial comparing continuous and short-term infusion. APMIS. 2019;127(12):779\u201388. https:\/\/doi.org\/10.1111\/apm.12996.","journal-title":"APMIS"},{"issue":"3","key":"1597_CR22","doi-asserted-by":"publisher","first-page":"E37","DOI":"10.1111\/j.1469-0691.2011.03752.x","volume":"18","author":"JW Mouton","year":"2012","unstructured":"Mouton JW, Brown DF, Apfalter P, Cant\u00f3n R, Giske CG, Ivanova M, et al. The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect. 2012;18(3):E37-45. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03752.x.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"1597_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","volume":"48","author":"CB Landersdorfer","year":"2009","unstructured":"Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, S\u00f6rgel F. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet. 2009;48(2):89\u2013124.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1597_CR24","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1128\/aac.31.6.935","volume":"31","author":"D Adam","year":"1987","unstructured":"Adam D, Heilmann HD, Weismeier K. Concentrations of ticarcillin and clavulanic acid in human bone after prophylactic administration of 5.2\u00a0g of timentin. Antimicrob Agents Chemother. 1987;31(6):935\u20139. https:\/\/doi.org\/10.1128\/aac.31.6.935.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1597_CR25","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ijantimicag.2015.01.008","volume":"45","author":"E As\u00edn-Prieto","year":"2015","unstructured":"As\u00edn-Prieto E, Soraluce A, Troc\u00f3niz IF, Campo Cimarras E, de S\u00e1enz Ugarte Sobr\u00f3n J, Rodr\u00edguez-Gasc\u00f3n A, et al. Population pharmacokinetic models for cefuroxime and metronidazole used in combination as prophylactic agents in colorectal surgery: model-based evaluation of standard dosing regimens. Int J Antimicrob Agents. 2015;45(5):504\u201311.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"1597_CR26","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/bcp.14556","volume":"87","author":"C Rimmler","year":"2021","unstructured":"Rimmler C, Lanckohr C, Mittrup M, Welp H, W\u00fcrthwein G, Horn D, et al. Population pharmacokinetic evaluation of cefuroxime in perioperative antibiotic prophylaxis during and after cardiopulmonary bypass. Br J Clin Pharmacol. 2021;87(3):1486\u201398.","journal-title":"Br J Clin Pharmacol"},{"key":"1597_CR27","doi-asserted-by":"crossref","unstructured":"Lanoisel\u00e9e J, Zufferey PJ, Hodin S, Tamisier N, Gergel\u00e9 L, Palao JC, et al. Pharmacokinetic model for cefuroxime dosing during cardiac surgery under cardiopulmonary bypass. Antimicrob Agents Chemother. 2020;64(12).","DOI":"10.1128\/AAC.01687-20"},{"issue":"3","key":"1597_CR28","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/jphp.13214","volume":"72","author":"U Gergs","year":"2020","unstructured":"Gergs U, Becker L, Okoniewski R, Weiss M, Delank KS, Neumann J. Population pharmacokinetics of cefuroxime and uptake into hip and spine bone of patients undergoing orthopaedic surgery. J Pharm Pharmacol. 2020;72(3):364\u201370. https:\/\/doi.org\/10.1111\/jphp.13214.","journal-title":"J Pharm Pharmacol"},{"issue":"6","key":"1597_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40262-020-00866-2","volume":"59","author":"A Aljutayli","year":"2020","unstructured":"Aljutayli A, Marsot A, Nekka F. An update on population pharmacokinetic analyses of vancomycin, part I: in adults. Clin Pharmacokinet. 2020;59(6):671\u201398. https:\/\/doi.org\/10.1007\/s40262-020-00866-2.","journal-title":"Clin Pharmacokinet"},{"issue":"2 Pt 1","key":"1597_CR30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/j.1875-9114.1983.tb04543.x","volume":"3","author":"B Gold","year":"1983","unstructured":"Gold B, Rodriguez WJ. Cefuroxime: mechanisms of action, antimicrobial activity, pharmacokinetics, clinical applications, adverse reactions and therapeutic indications. Pharmacotherapy. 1983;3(2 Pt 1):82\u2013100.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"1597_CR31","first-page":"69","volume":"32","author":"MP Doogue","year":"2011","unstructured":"Doogue MP, Polasek TM. Drug dosing in renal disease. Clin Biochem Rev. 2011;32(2):69\u201373.","journal-title":"Clin Biochem Rev"},{"issue":"2","key":"1597_CR32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/jac\/dkm476","volume":"61","author":"JW Mouton","year":"2008","unstructured":"Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. Tissue concentrations: do we ever learn? J Antimicrob Chemother. 2008;61(2):235\u20137. https:\/\/doi.org\/10.1093\/jac\/dkm476.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1597_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23100","volume":"34","author":"JJ van Raaij","year":"2020","unstructured":"van Raaij JJ, Mabelis NJD, Shudofsky KN, Meenks SD, le Nob J, Janssen PKC. Quantification of total and unbound cefuroxime in plasma by ultra-performance liquid chromatography tandem mass spectrometry in a cohort of critically ill patients with hypoalbuminemia and renal failure. J Clin Lab Anal. 2020;34(3):e23100. https:\/\/doi.org\/10.1002\/jcla.23100.","journal-title":"J Clin Lab Anal"},{"issue":"6","key":"1597_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae203","volume":"6","author":"Y Abouelhassan","year":"2024","unstructured":"Abouelhassan Y, Kuti JL, Nicolau DP, Abdelraouf K. Pharmacokinetic\/pharmacodynamic analysis of sulbactam against Acinetobacter baumannii pneumonia: establishing in vivo efficacy targets in the epithelial lining fluid. JAC Antimicrob Resist. 2024;6(6):dlae203. https:\/\/doi.org\/10.1093\/jacamr\/dlae203.","journal-title":"JAC Antimicrob Resist"},{"issue":"4","key":"1597_CR35","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02181-21","volume":"66","author":"N Farrington","year":"2022","unstructured":"Farrington N, McEntee L, Johnson A, Unsworth J, Darlow C, Jimenez-Valverde A, et al. Pharmacodynamics of meropenem and tobramycin for neonatal meningoencephalitis: novel approaches to facilitate the development of new agents to address the challenge of antimicrobial resistance. Antimicrob Agents Chemother. 2022;66(4):e0218121. https:\/\/doi.org\/10.1128\/aac.02181-21.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01597-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01597-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01597-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T14:38:15Z","timestamp":1772635095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01597-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1597"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01597-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted as part of our clinical work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Birgit C.P. Koch is an Editorial Board member of Clinical Pharmacokinetics but had no role in the review of or editorial decisions regarding this manuscript. No other conflicts of interest were declared by any authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed according to the Declaration of Helsinki and was approved by the Ethics Committee of the Erasmus MC in September 2020 (approval no. MEC-2020-0279).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All research participants provided written informed consent before inclusion in the study for the use of their data for analysis and publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All relevant data are mentioned in the manuscript or in the Supplementary Material. Any additional reasonable data request can be sent to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The NONMEM control stream produced during this study of both the base and final model is included in the Supplementary Material.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Gerbert Coen de Waard conducted model analysis and manuscript preparation. Qiaolin Zhao conducted model analysis and manuscript preparation. Ewout S. Veltman, Jakob van Oldenrijk, and P.K. (Koen) Bos designed this study. Soma Bahmany performed the laboratory analysis. Anouk Muller and Birgit C.P. Koch reviewed and approved the manuscript before submission. Tim Preijers guided the model building and reviewed and approved the manuscript before submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}